In this Business Breakdown, David Barbato and Christian Schmidt sit down with Iridex’s (NASDAQ: IRIX) CEO Patrick Mercer and CFO Romeo Dizon. The company was originally profiled by member “jbhw28” on December 17, 2013, at $8.64 USD per share.

This discussion took place live on February 27th, 2026, on the MicroCapClub Community. Join MicroCapClub and unlock the ability to listen and participate live in these discussions - https://microcapclub.com/join-now/

This comprehensive interview with Patrick Mercer and Romeo Dizon of Iridex covers the company's strategic focus, financial turnaround, product portfolio, market opportunities, and future plans. Gain insights into how Iridex is positioning itself for growth in ophthalmic laser technology and the healthcare industry.

✉️ Share your feedback - david@microcapclub.com

✉️ David’s X (Twitter) - https://x.com/Valuehunte

Chapters

00:00 Introduction and Professional Backgrounds

04:57 Business Performance and Financial Overview

11:09 Retina Products and Market Opportunities

14:06 Glaucoma Treatment Innovations and Market Potential

19:34 Sales Strategy and Financial Health

22:02 Q&A: Addressing Profitability Concerns

26:25 Reimbursement Environment and Its Impact

28:59 Socioeconomic Considerations in Glaucoma Treatment

30:21 Drivers of Revenue Growth

32:43 Future Acquisition Plans and Strategic Moves

37:03 Understanding Cash Injection and Equity Alternatives

37:45 Exploring the Relationship with Novel

38:49 Competitive Landscape and Pricing Strategies

40:43 Sales Force Efficiency and Company Strategy

42:48 Evaluating Future Sales Force Expansion

43:40 Operational Changes and Cost Management

47:41 Headquarters Relocation and Employee Impact

49:41 Prioritizing Cost Savings and Operational Efficiency

52:46 CEO Adaptation and Investor Relations

55:49 Future Outlook and Accountability Metrics

Disclaimer: All content on this channel is for discussion, education, entertainment, and illustrative purposes only and SHOULD NOT be construed as professional financial advice, solicitation, or recommendation to buy or sell any securities, notwithstanding anything stated on this channel. There are risks associated with investing in securities. Loss of principal is possible. Past performance is not a predictor of future investment performance. Ian Cassel and the guests on this channel are not responsible for investment actions taken by viewers. Should you need such advice, consult a licensed financial advisor, legal advisor, or tax advisor. You agree to verify all information yourself before investing. Any past performance discussed during this program is no guarantee of future results. Investing involves risk and possible loss of principal capital; please seek advice from a licensed professional. All views expressed are personal opinions as of the date of recording and are subject to change without the responsibility to update views. No guarantee is given regarding the accuracy of the information on this channel. Releasees undertake no obligation to provide accurate or sound investment statements. You waive any and all duties that may exist flowing from you to any Releasee. You agree not to hold any Releasee liable for any possible claim for damages arising from any decision you make based on information or other content on the Channel.

Iridex Corp (NASDAQ: IRIX): Transforming Eye Care

MicroCapClub